Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the University of Pennsylvania. The Food and Drug Administration gave orphan drug status to SynKIR-110, a CAR T-cell therapy utilized for[…]
Peritoneal Mesothelioma
Allocetra and Cisplatin Combination for Mesothelioma
A new immunotherapy treatment is showing promising results against mesothelioma. The therapy consists of a combination of two drugs: one drug that reprograms macrophages and the other is the chemotherapy cisplatin. Mesothelioma is a cancer that does not respond well to treatment. The best option for patients is a combination[…]
Tool to Measure Asbestos Levels in Tissue has Been Created
A new tool to determine levels of asbestos exposure has been developed. The tool, created by Italian researchers, is known as a Retrospective Exposure Assessment (REA). The tool uses a microscope to determine how much asbestos is in lung tissue. The study wants to compare the actual level of asbestos[…]
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Primary Outcome Measures Determine DLTs and RP2Ds in AMXT 1501 in combination with IV DFMO [ Time Frame: 1 year ] Indicate Number of patients with DLTs in AMXT1501 in combination with IV DFMO in patients with advanced cancer to determine the RP2D within the duration of the dose escalation period of the study[…]
Researchers Found a Relationship Between GISTs and Peritoneal Mesothelioma
Scientists may have found an easy way to identify peritoneal mesothelioma, making it easier to detect and catch the cancer earlier. These researchers may have found a link between peritoneal mesothelioma and gastrointestinal stromal tumors. The research done in the division of surgical oncology at University of California San Diego[…]
Report Shows that Asbestos Ban Would Benefit Countries Around the World
Banning asbestos could soon be a reality after a study linked asbestos, a toxic naturally occurring mineral, to mesothelioma, lung cancer, and other cancers. The report linked asbestos with different asbestos related diseases in 70 countries. The report was published in May by Environmental Health Perspectives, which is supported by[…]
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Primary Outcome Measures Phase 1 – Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events. [ Time Frame: DLTs within 28 days post-treatment ] Phase 1 -The number and percent of patients in the DLT evaluable set who experienced DLTs from the first administration of study drug[…]
Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma (INTERACT MESO)
Primary Outcome Measures The maximum tolerable dose (MTD) [ Time Frame: After two completed cycles of therapy (each cycle is 1 week) ] The primary endpoint of the study is to determine the maximum tolerable dose (MTD) of intraperitoneal (IP) paclitaxel monotherapy, for patients with malignant peritoneal mesothelioma (MPM) who are not eligible to[…]
Vudalimab for the Treatment of Mesothelioma
The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Primary Objective Efficacy of XmAb20717 as defined by objective response (defined as a complete response [CR] or partial response [PR] on two consecutive occasions ≥4 weeks apart) as determined by an independent radiologist according to RECIST v1.1 (modified RECIST for pleural mesothelioma) Secondary Objective Objective response as determined by an[…]
